{
    "root": "c3a72be7-f3d7-45dd-b21c-83222a176c9c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CHLORZOXAZONE",
    "value": "20250316",
    "ingredients": [
        {
            "name": "CHLORZOXAZONE",
            "code": "H0DE420U8G"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        }
    ],
    "indications": "chlorzoxazone indicated adjunct rest , physical therapy , measures relief discomfort associated acute , painful musculoskeletal conditions . mode action clearly identified , may related sedative properties . chlorzoxazone directly relax tense skeletal muscles man .",
    "contraindications": "usual adult : one tablet ( 250 mg ) three four times daily . initial painful musculoskeletal conditions two tablets ( 500 mg ) three four times daily . adequate response obtained dose , may increased three tablets ( 750 mg ) three four times daily . improvement occurs usually reduced .",
    "warningsAndPrecautions": "chlorzoxazone tablets , usp , 250 mg supplied white off-white , capsule shaped , uncoated tablets debossed \u201c c15 \u201d one side plain side . bottles 30 tablets ndc 31722-974-30 bottles 60 tablets ndc 31722-974-60 bottles 100 tablets ndc 31722-974-01 bottles 500 tablets ndc 31722-974-05 bottles 1000 tablets ndc 31722-974-10 dispense tight container defined usp . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . manufactured : camber pharmaceuticals , inc. piscataway , nj 08854. manufactured : corepharma , llc . 215 wood ave , middlesex , nj 08846 revised : 02/2022 40033",
    "adverseReactions": "chlorzoxazone contraindicated patients known intolerance .",
    "indications_original": "Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.",
    "contraindications_original": "Usual Adult Dosage: One tablet (250 mg) three or four times daily. Initial dosage for painful musculoskeletal conditions should be two tablets (500 mg) three or four times daily. If adequate response is not obtained with this dose, it may be increased to three tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.",
    "warningsAndPrecautions_original": "Chlorzoxazone tablets, USP, 250 mg are supplied as white to off-white, capsule shaped, uncoated tablets debossed with \u201cC15\u201d on one side and plain on other side.\n                  Bottles of 30 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-974-30\n                  Bottles of 60 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-974-60\n                  Bottles of 100 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-974-01\n                  Bottles of 500 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-974-05\n                  Bottles of 1000 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-974-10\n                  Dispense in tight container as defined in the USP.\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                     Manufactured for:\n                  \n                  \n                     \n                     \n                     Camber Pharmaceuticals, Inc.\n                     Piscataway, NJ 08854.\n                  \n                     Manufactured by:\n                     \n                     CorePharma, LLC.\n                     215 Wood Ave, Middlesex, NJ 08846\n                  Revised: 02/2022\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 40033",
    "adverseReactions_original": "Chlorzoxazone is contraindicated in patients with known intolerance to the drug."
}